Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate

Modern Pathology

Volumn 22, Issue 10, 2009, Pages 1273-1279

  Sanati, Souzan ^a   Watson, Mark A ^a   Salavaggione, Andrea L ^a   Humphrey, Peter A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Ductal; Gene; Neoplasms; Prolactin; Prostate

Indexed keywords

PROLACTIN RECEPTOR; RNA;

ACINAR CELL CARCINOMA; ARTICLE; CANCER TISSUE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC DIFFERENCE; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MICRODISSECTION; PRIORITY JOURNAL; PROSTATE; RNA ISOLATION;

CARCINOMA, ACINAR CELL; CARCINOMA, DUCTAL; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICRODISSECTION; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; RECEPTORS, PROLACTIN; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 70349668971     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.103     Document Type: Article

References (35)

1. Grignon DJ. Unusual subtypes of prostate cancer. Mod Pathol 2004;17:316-327.
2. Humphrey PA. Variants of prostatic carcinoma (Chapter 17). In: Prostate Pathology ASCP Press: Chicago, 2003, pp 390-400.
3. Yang XJ, Cheng L, Helpap B, et al. Ductal adenocarcinoma In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, (eds) Tumours of the Urinary System and Male Genital Organs. IARC Press: Lyon, France, 2004, pp 199-201.
4. Young RH, Srigley JR, Amin MB, et al (eds). Variants of prostatic adenocarcinoma, other primary carcinomas of prostate, and secondary carcinomas (Chapter 5) and miscellaneous tumors of the prostate (Chapter 6). In: Tumors of the Prostate Gland, Seminal Vesicles, Male Urethra, and Penis, Third Series, Fascicle 28. Armed Forces Institute of Pathology: Washington DC, 2000;217-288.
5. Bock BJ, Bostwick DG. Does prostatic ductal adenocarcinoma exist? Am J Surg Pathol 1999;23:781-785.
6. Dube VE, Farrow GM, Greene LF. Prostatic adenocarcinoma of ductal origin. Cancer 1973;32:402-409.
7. Bostwick DG, Kindrachuk RW, Rouse RV. Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am J Surg Path 1985;9:595-609.
8. Brinker DA, Potter SR, Epstein JI. Ductal adenocarcinom of the prostate diagnosed on needle biopsy. Correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol 1999; 23:1471-1479.
9. Samaratunga H, Delahunt B. Ductal adenocarcinoma of the prostate: current opinion and controversies. Anal Quant Cytol Histol 2008;30:237-246.
10. Lemberger RJ, Bishop MC, Bates CP, et al. Carcinoma of the prostate of ductal origin. Br J Urol 1984;56:706-709.
11. Christensen WN, Steinberg G, Walsh PC, et al. Prostatic duct adenocarcinoma. Findings at radical prostatectomy. Cancer 1991;67:2118-2124.
12. Epstein JI, Woodruff JM. Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases. Cancer 1986;57:111-119.
13. Greene LF, Farrow GM, Ravits JM, et al. Prostatic adenocarcinoma of ductal origin. J Urol 1979;121:303-305.
14. Ro JY, Ayala AG, Wishnow KI, Ordoñez NG. Prostatic duct adenocarcinoma with endometrioid features: immunohistochemical and electron microscopic study. Semin Diagn Pathol 1988;5:301-311.
15. Gong Y, Caraway N, Stewart J, et al. Metastatic ductal adenocarcinoma of the prostate: cytologic features and clinical findings. Am J Clin Pathol 2006;126:302-309.
16. Leite KR, Mitteldorf CA, Srougi M, et al. Cdx2, cytokeratin 20, thyroid transcription factor 1, and prostate-specific antigen expression in unusual subtypes of prostate cancer. Ann Diag Pathol 2008;12: 260-266.
17. Copeland JN, Amin MB, Humphrey PA, et al. The morphologic spectrum of metastatic prostatic adenocarcinoma to the lung: special emphasis on histologic features overlapping with other pulmonary neoplasms. Am J Clin Pathol 2002;117:552-557.
18. Oxley JD, Abbott CD, Gillatt DA, et al. Ductal adenocarcinoma of the prostate: a clinicopathologic and immunohistochemical study. Br J Urol 1998;81: 109-115.
19. Lee SS. Endometrioid adenocarcinoma of the prostate: a clinicopathologic and immunohistochemical study. J Surg Oncol 1994;55:235-238.
20. Millar EK, Sharma NK, Lessells AM. Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathologic study of 16 cases. Histopathology 1996;29:11-19.
21. Samaratunga H, Singh M. Distribution pattern of basal cells detected by cytokeratin 34betaE12 in primary prostatic duct adenocarcinoma. Am J Surg Pathol 1997;21:435-440.
22. Beach R, Gown AM, de Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 2002;26:1588-1596.
23. Herawi M, Epstein JI. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Am J Surg Pathol 2007;31:889-894.
24. Wang H, Adley B, Keleman K, et al. Decreased expression of alpha-methylacyl coenzyme A racemase in prostatic ductal adenocarcinoma. Mod Pathol 2006;19(Suppl 3):89 (abstract).
25. Rioux-Leclercq N, Leray E, Patard JJ, et al. The utility of Ki-67 expression in the differential diagnosis of prostatic intraepithelial neoplasia and ductal adenocarcinoma. Hum Pathol 2005;36:531-535.
26. Sharma MK, Mansur DB, Reifenberger G, et al. Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res 2007;67:890-900.
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Sat Soc, Ser B 1995;57:289-300.
28. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-5121.
29. Lotan TL, Toubaji A, Albadine R, et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinoma. Mod Pathol 2009;22:359-365.
30. Tulunay O, Orhan D, Baltaci S, et al. Prostatic ductal adenocarcinoma showing Bcl-2 expression. Int J Urol 2004;11:805-808.
31. Kristiansen G, Sammar M, Altevogt P. Tumor biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004;35:255-262.
32. Ingelmo I, Gomez V, Martin R, et al. Effect of prolactin and bromocriptine on the population of prostate neuroendocrine cells from intact and cyproterone acetate-treated rats: stereological and immunohistochemical study. Anat Rec 2007;290:855-861.
33. Nevalainen MT, Valve EM, Ingleton PM, et al. Prolactin and prolactin receptor are expressed and functioning in human prostate. J Clin Invest 1997;99: 618-627.
34. Kindblom J, Dillner K, Sahlin L, et al. Prostate hyperplasia in a transgenic mouse with prostatespecific expression of prolactin. Endocrinology 2003;144:2269-2278.
35. Dagvadorj A, Collins S, Jomain JB, et al. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology 2007;148:3089-3101.